MED — Medifast Share Price
0.000.00%
Last trade - 00:00- $130.38m
- -$31.97m
- $602.46m
- 99
- 96
- 42
- 93
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.62 | ||
| Price to Tang. Book | 0.62 | ||
| Price to Free Cashflow | 7.66 | ||
| Price to Sales | 0.22 | ||
| EV to EBITDA | -1.62 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.31% | ||
| Return on Equity | 1.02% | ||
| Operating Margin | 0.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 934.84 | 1,526.09 | 1,598.58 | 1,072.05 | 602.46 | 406.1 | 394.1 | -3.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +42.07 | +51.99 | -8.31 | -28.5 | -90.99 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA, which provides people with a comprehensive approach to address obesity and support a healthy lifestyle. OPTAVIA provides coaching support along with community, tailored nutrition, and healthy habits, and helps people in their weight-loss journey through each stage of life. Through its collaboration with national virtual primary care provider LifeMD, Inc. and its affiliated medical group, customers have access to GLP-1 medications where clinically appropriate. It sells a variety of weight-loss, weight management and healthy living products all based on its proprietary formulas under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brands. Its product line includes approximately 79 consumable options, including bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups.
Directors
- Daniel Chard CHM (56)
- James Maloney CFO (53)
- Jason Groves EVP (50)
- Claudia Greninger EVP (48)
- William Baker EVP (49)
- Nicholas Johnson EVP (41)
- Lauren Walker EVP (54)
- Jonathan Mackenzie CAO (50)
- Anthony Tyree CMO (55)
- Jeffrey Brown LED (60)
- Kevin Byrnes IND (74)
- Constance Hallquist IND (57)
- Michael Hoer IND
- Scott Schlackman IND (63)
- Andrea Thomas IND (56)
- Ming Xian IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 5th, 1989
- Public Since
- December 30th, 1993
- No. of Shareholders
- 66
- No. of Employees
- 504
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- New York Stock Exchange
- Shares in Issue
- 10,937,830
- Address
- 100 International Drive, 18th Floor, BALTIMORE, 21202
- Web
- https://medifastinc.com/
- Phone
- +1 4105818042
- Auditors
- RSM US LLP
Upcoming Events for MED
Q1 2025 Medifast Inc Earnings Call
Medifast Inc Annual Shareholders Meeting
Q2 2025 Medifast Inc Earnings Release
Similar to MED
Adecoagro SA
New York Stock Exchange
Altria
New York Stock Exchange
Archer-Daniels-Midland Co
New York Stock Exchange
B&G Foods
New York Stock Exchange
Bellring Brands
New York Stock Exchange
FAQ
What is the Medifast share price?
As of Today at 21:58 UTC, shares in Medifast are trading at $11.92. This share price information is delayed by 15 minutes.
How has the Medifast share price performed this year?
Shares in Medifast last closed at $11.92 and the price had moved by -62.61% over the past 365 days. In terms of relative price strength the Medifast share price has underperformed the S&P500 Index by -64.84% over the past year.
What are the analyst and broker recommendations for Medifast?
The overall consensus recommendation for Medifast is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medifast dividend yield?
Medifast does not currently pay a dividend.
Does Medifast pay a dividend?
Medifast does not currently pay a dividend.
When does Medifast next pay dividends?
Medifast does not currently pay a dividend.
How do I buy Medifast shares?
To buy shares in Medifast you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medifast?
As of the previous close price of $11.92, shares in Medifast had a market capitalisation of $130.38m.
Where are Medifast shares listed?
Here are the trading details for Medifast:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: MED
What kind of share is Medifast?
Based on an overall assessment of its quality, value and momentum Medifast is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medifast share price forecast for 2025?
The analyst consensus target price for shares in Medifast is $15.00. That is 25.84% above the last closing price of $11.92.
Analysts covering Medifast currently have a consensus Earnings Per Share (EPS) forecast of -$1.05 for the next financial year.
Find out moreWhat is the trend in the Medifast share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medifast. Over the past six months, its share price has underperformed the S&P500 Index by -27.06%.
As of the last closing price of $11.92, shares in Medifast were trading -31.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medifast PE Ratio?
The Medifast PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medifast?
Medifast's management team is headed by:
- Daniel Chard - CHM
- James Maloney - CFO
- Jason Groves - EVP
- Claudia Greninger - EVP
- William Baker - EVP
- Nicholas Johnson - EVP
- Lauren Walker - EVP
- Jonathan Mackenzie - CAO
- Anthony Tyree - CMO
- Jeffrey Brown - LED
- Kevin Byrnes - IND
- Constance Hallquist - IND
- Michael Hoer - IND
- Scott Schlackman - IND
- Andrea Thomas - IND
- Ming Xian - IND